Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ADC Therapeutics (ADCT) Accounts Payables (2019 - 2023)

Historic Accounts Payables for ADC Therapeutics (ADCT) over the last 5 years, with Q3 2023 value amounting to $9.0 million.

  • ADC Therapeutics' Accounts Payables fell 2268.54% to $9.0 million in Q3 2023 from the same period last year, while for Sep 2023 it was $9.0 million, marking a year-over-year decrease of 2268.54%. This contributed to the annual value of $12.4 million for FY2022, which is 10214337.75% up from last year.
  • As of Q3 2023, ADC Therapeutics' Accounts Payables stood at $9.0 million, which was down 2268.54% from $11.7 million recorded in Q2 2023.
  • Over the past 5 years, ADC Therapeutics' Accounts Payables peaked at $16.5 million during Q1 2022, and registered a low of $3329.0 during Q4 2019.
  • In the last 5 years, ADC Therapeutics' Accounts Payables had a median value of $11.5 million in 2021 and averaged $8.6 million.
  • As far as peak fluctuations go, ADC Therapeutics' Accounts Payables skyrocketed by 21515673.09% in 2021, and later crashed by 4715.86% in 2023.
  • Over the past 5 years, ADC Therapeutics' Accounts Payables (Quarter) stood at $3329.0 in 2019, then soared by 84.62% to $6146.0 in 2020, then skyrocketed by 96.55% to $12080.0 in 2021, then soared by 102143.38% to $12.4 million in 2022, then dropped by 27.32% to $9.0 million in 2023.
  • Its Accounts Payables stands at $9.0 million for Q3 2023, versus $11.7 million for Q2 2023 and $8.7 million for Q1 2023.